Cuprina Holdings (Cayman) Limited announced on June 15, 2026, that it received clearance from the U.S. Food and Drug Administration (FDA) for its MEDIFLY Maggots product. The company operates in the biotechnology industry, focusing on medical applications.

Cuprina Holdings (Cayman) Limited has regained compliance with the Nasdaq Minimum Bid Price Rule, which requires a minimum bid price of at least $1.00 per share. Following a period of non-compliance and a hearing request filed on May 28, 2026, the company received notification on June 11, 2026, that it is now in compliance with Nasdaq Capital Market listing requirements. As a result, the scheduled July 7, 2026 hearing has been cancelled and the company's Class A Ordinary Shares will continue to be listed on the Nasdaq Stock Market. Cuprina Holdings is a company that operates in the healthcare sector, providing medical services and products.